Get notified when ASMB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAssembly Biosciences expands ABI-6250 into two new liver diseases, Phase 2 trials to start Q4 2026
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Company expanding ABI-6250 drug candidate beyond hepatitis delta virus into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), significantly broadening potential market opportunity into cholestatic liver diseases.
Item 8.01: Press Release verify on EDGAR → -
high
Phase 2 trial for hepatitis delta virus planned for Q4 2026, with separate Phase 2 basket study for PBC and PSC expected Q1 2027 pending regulatory feedback.
Item 8.01: Press Release verify on EDGAR → -
medium
Phase 1a data confirmed drug's mechanism of action through dose-dependent bile acid increases; completed chronic toxicology studies support longer-term dosing in upcoming trials.
Item 8.01: Press Release verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade ASMB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 27, 2026 · How we verify